Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease

Bibliography

• Clark CM, Karlawish JH. Alzheimer disease: current concepts and emerging diagnostic and therapeutic strategies. Ann Intern Med 2003;11:400-10
   Google Scholar
• Nussbaum RL, Ellis CE. Alzheimer's disease and Parkinson's disease. N Engl J Med 2003;348:1356-64
   PubMed Web of Science ®Google Scholar
• Hy LX, Keller DM. Prevalence of AD among whites: a summary by levels of severity. Neurology 2000;55:198-204
   PubMed Web of Science ®Google Scholar
• Ferri CP, Prince M, Brayne C, Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366:2112-7
   PubMed Web of Science ®Google Scholar
• World Alzheimer Report 2009, Executive Summary. Available from: http://www.alz.co.uk/research/files/WorldAlzheimerReport-ExecutiveSummary.pdf. [Last accessed 30 March 2010]
   Google Scholar
• Kosasa T, Kuriya Y, Matsui K, Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats. Eur J Pharmacol 2000;389:173-9
   PubMed Web of Science ®Google Scholar
• Yamada K, Takayanagi M, Kamei H, Effects of memantine and donepezil on amyloid beta-induced memory impairment in a delayed-matching to position task in rats. Behav Brain Res 2005;162:191-9
   PubMed Web of Science ®Google Scholar
• Perry EK, Tomlinson BE, Blessed G, Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. BMJ 1978;2:1457-9
   PubMed Web of Science ®Google Scholar
• Bleich S, Romer K, Wiltfang J. Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003;18:S33-4
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG, Bresink I, Glutamate in CNS disorders. Drug News Perspect 1995;8:261-77
   Google Scholar
• Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs 2000;60:1095-122
   PubMed Web of Science ®Google Scholar
• Lancelot E, Beal MF. Glutamate toxicity in chronic neurodegenerative disease. Prog Brain Res 1998;116:331-47
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003;18:S23-32
   Google Scholar
• Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology 1999;38:735-67
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Arch Neurol 2006;63:49-54
   PubMed Web of Science ®Google Scholar
• Tariot PN, Farlow MR, Grossberg GT, Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24
   PubMed Web of Science ®Google Scholar
• Reisberg B, Doody R, Stoffler A, Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-41
   PubMed Web of Science ®Google Scholar
• McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev 2006;2:CD003154
   PubMedGoogle Scholar
• Thomas S, Grossberg GT. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 2009;4:367-77
   PubMed Web of Science ®Google Scholar
• Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system – too little activation is bad, too much is even worse. Neuropharmacology 2007;53:699-723
   PubMed Web of Science ®Google Scholar
• Namenda®: US Prescribing Information. St. Louis, MO: Forest Pharmaceuticals, Inc., April 2007
   Google Scholar
• Karlawish JH, Casarett DJ, James BD, The ability of persons with Alzheimer disease (AD) to make a decision about taking an AD treatment. Neurology 2005;64:1514-9
   PubMed Web of Science ®Google Scholar
• Pruchno RA, Smyer MA, Rose MS, Competence of long-term care residents to participate in decisions about their medical care: a brief, objective assessment. Gerontologist 1995;35:622-9
   PubMed Web of Science ®Google Scholar
• Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995;56(Suppl 1):18-23
   PubMed Web of Science ®Google Scholar
• Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med 1990;150:841-5
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association and National Alliance for Caregiving. Families care: Alzheimer's caregiving in the United States 2004. Available from: http://www.alz.org/national/documents/report_familiescare.pdf. [Last accessed 30 March 2010]
   Google Scholar
• Alzheimer's Association. Statistics about Alzheimer's Disease. Available from: http://www.alz.org/AboutAD/statistics.asp. [Last accessed 30 March 2010]
   Google Scholar
• Delagarza VW. Pharmacologic treatment of Alzheimer's disease: an update. Am Fam Physician 2003;68:1365-72
   PubMed Web of Science ®Google Scholar
• Cuijpers P. Depressive disorders in caregivers of dementia patients: a systematic review. Aging Ment Health 2005;9:325-30
   PubMed Web of Science ®Google Scholar
• Slattum PW, Johnson MA. Caregiver burden in Alzheimer's disease. Consult Pharm 2004;19:352-62
   PubMedGoogle Scholar
• Oertel W, Ross JS, Eggert K, Rationale for transdermal drug administration in Alzheimer disease. Neurology 2007;69(Suppl 1):S4-9
   Google Scholar
• Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs 2009;23:293-307
   PubMed Web of Science ®Google Scholar
• Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 2008;31:577-85
   PubMed Web of Science ®Google Scholar
• Jones R, Bayer A, Inglis F, Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry 2007;22:258-62
   PubMed Web of Science ®Google Scholar
• Winblad B, Poritis N. Memantine in severe dementia: results of the M-BEST Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46
   PubMed Web of Science ®Google Scholar
• Kornhuber J, Kennepohl EM, Bleich S, Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007;46:599-612
   PubMed Web of Science ®Google Scholar
• Peskind ER, Potkin SG, Pomara N, Memantine MEM-MD-10 Study Group. Memantine treatment in mild to moderate Alzheimer disease: a 24 week randomized, controlled trial. Am J Geriatr Pyschiatry 2004;14:704-15
   Web of Science ®Google Scholar
• Ott BR, Blake LM, Kagan E, Open label, multicenter, 28-week extension study of the safety and tolerability of memantine in patients with mild to moderate Alzheimer's disease. J Neurol 2007;254:351-8
   PubMed Web of Science ®Google Scholar
• Porsteinsson A, Grossberg G, Mintzer J, ; for the Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 2008;5:83-9
   PubMed Web of Science ®Google Scholar
• Farlow MR, Graham SM, Alva G. Memantine for the treatment of Alzheimer's disease: tolerability and safety data from clinical trials. Drug Saf 2008;31:577-85
   PubMed Web of Science ®Google Scholar
• Periclou A, Hu Y. Extended-release memantine capsule (28 mg, once daily): a multiple dose, open-label study evaluating steady-state pharmacokinetics in healthy volunteers [abstract from poster presentation]. Presented at the 11th International Conference on Alzheimer's Disease, 26 – 31 July 2008; Chicago, IL, USA
   Google Scholar
• van Marum RJ. Update on the use of memantine in Alzheimer's disease. Neuropsychiatr Dis Treat 2009;5:237-47
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Manes F, Allegri R, A multinational, randomized, double-blind, placebo-controlled, parallel-group trial of memantine extended-release capsule (28 mg, once daily) in patients with moderate to severe Alzheimer's disease [abstract from poster presentation]. Presented at the 11th International Conference on Alzheimer's Disease, 26 – 31 July 2008; Chicago, IL, USA
   Google Scholar